Brovana Articles
Sepracor's 1st-qtr revenues jump 3%
5 May 2009
Nycomed licenses US rights to ciclesonide drugs to Sepracor in deal worth up to $430M
4 February 2008
Sepracor submits COPD NDA on arformoterol
19 December 2005
Showing 1-5 of 5 articles
- 1
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
